BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28430398)

  • 1. Impact of Acid-Reducing Agents on the Pharmacokinetics of Palbociclib, a Weak Base With pH-Dependent Solubility, With Different Food Intake Conditions.
    Sun W; Klamerus KJ; Yuhas LM; Pawlak S; Plotka A; O'Gorman M; Kirkovsky L; Kosa M; Wang D
    Clin Pharmacol Drug Dev; 2017 Nov; 6(6):614-626. PubMed ID: 28430398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of food on the bioavailability of palbociclib.
    Ruiz-Garcia A; Plotka A; O'Gorman M; Wang DD
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):527-533. PubMed ID: 28204912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of food and the proton pump inhibitor rabeprazole on the pharmacokinetics of GDC-0941 in healthy volunteers: bench to bedside investigation of pH-dependent solubility.
    Ware JA; Dalziel G; Jin JY; Pellett JD; Smelick GS; West DA; Salphati L; Ding X; Sutton R; Fridyland J; Dresser MJ; Morrisson G; Holden SN
    Mol Pharm; 2013 Nov; 10(11):4074-81. PubMed ID: 24099279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib.
    Malhi V; Colburn D; Williams SJ; Hop CE; Dresser MJ; Chandra P; Graham RA
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):41-9. PubMed ID: 27154174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers.
    Ruiz-Garcia A; Masters JC; Mendes da Costa L; LaBadie RR; Liang Y; Ni G; Ellery CA; Boutros T; Goldberg Z; Bello CL
    J Clin Pharmacol; 2016 Feb; 56(2):223-30. PubMed ID: 26179237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the Moderate CYP3A4 Inhibitor Erythromycin on the Pharmacokinetics of Palbociclib: A Randomized Crossover Trial in Patients With Breast Cancer.
    Molenaar-Kuijsten L; Braal CL; Groenland SL; de Vries N; Rosing H; Beijnen JH; Koolen SLW; Vulink AJE; van Dongen MGJ; Mathijssen RHJ; Huitema ADR; Steeghs N;
    Clin Pharmacol Ther; 2022 Feb; 111(2):477-484. PubMed ID: 34674222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Relative Bioavailability and Effects of Food and Acid-Reducing Agents on Filgotinib Tablets in Healthy Subjects.
    Anderson K; Zheng H; Kotecha M; Cuvin J; Scott B; Sharma S; Qin AR; Namour F; Xin Y
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):585-594. PubMed ID: 30768860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.
    Kletzl H; Giraudon M; Ducray PS; Abt M; Hamilton M; Lum BL
    Anticancer Drugs; 2015 Jun; 26(5):565-72. PubMed ID: 25643050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects.
    Eley T; Luo FR; Agrawal S; Sanil A; Manning J; Li T; Blackwood-Chirchir A; Bertz R
    J Clin Pharmacol; 2009 Jun; 49(6):700-9. PubMed ID: 19395585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of the Human Upper Gastrointestinal Contents in the Fasted State Under Hypo- and A-chlorhydric Gastric Conditions Under Conditions of Typical Drug - Drug Interaction Studies.
    Litou C; Vertzoni M; Goumas C; Vasdekis V; Xu W; Kesisoglou F; Reppas C
    Pharm Res; 2016 Jun; 33(6):1399-412. PubMed ID: 26975361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of the antacid Maalox and the H2-antagonist cimetidine on the pharmacokinetics of cerivastatin.
    Mück W; Ritter W; Dietrich H; Frey R; Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Jun; 35(6):261-4. PubMed ID: 9208343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3.
    Narumi K; Sato Y; Kobayashi M; Furugen A; Kasashi K; Yamada T; Teshima T; Iseki K
    Biopharm Drug Dispos; 2017 Dec; 38(9):501-508. PubMed ID: 28801980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of food and gastric pH on the bioavailability of grepafloxacin.
    Efthymiopoulos C; Bramer SL; Maroli A
    Clin Pharmacokinet; 1997; 33 Suppl 1():18-24. PubMed ID: 9433652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically Based Pharmacokinetic Modeling of Palbociclib.
    Yu Y; Loi CM; Hoffman J; Wang D
    J Clin Pharmacol; 2017 Feb; 57(2):173-184. PubMed ID: 27402157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of rabeprazole alone or in combination with H2 receptor blocker on intragastric pH: a pilot study.
    Törüner M; Bektaş M; Cetinkaya H; Soykan I; Ozden A
    Turk J Gastroenterol; 2004 Dec; 15(4):225-8. PubMed ID: 16249975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants.
    Xu H; O'Gorman MT; Nepal S; James LP; Ginman K; Pithavala YK
    Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1395-1404. PubMed ID: 34288547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach.
    Sun W; O'Dwyer PJ; Finn RS; Ruiz-Garcia A; Shapiro GI; Schwartz GK; DeMichele A; Wang D
    J Clin Pharmacol; 2017 Sep; 57(9):1159-1173. PubMed ID: 28419480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients.
    Takahashi N; Miura M; Niioka T; Sawada K
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):999-1004. PubMed ID: 22147077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of gastric acid-reducing agents on the pharmacokinetics and efficacy of lemborexant.
    Landry I; Aluri J; Hall N; Kumar D; Dayal S; Moline M; Reyderman L
    Pharmacol Res Perspect; 2020 Dec; 8(6):e00678. PubMed ID: 33135390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria.
    Yago MR; Frymoyer A; Benet LZ; Smelick GS; Frassetto LA; Ding X; Dean B; Salphati L; Budha N; Jin JY; Dresser MJ; Ware JA
    AAPS J; 2014 Nov; 16(6):1358-65. PubMed ID: 25274610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.